Elacestrant
ESR1 Gene Mutation
Kristina A. FanucciSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the ESR1 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus MedSIR | Phase 3 | B |
DEXAMETHASONE MedSIR | Phase 3 | B |
Capecitabine Kristina A. Fanucci | Phase 2 | CCC |
Eloxatin Kristina A. Fanucci | Phase 2 | CCC |
TAMOXIFEN University of Wisconsin, Madison | Early Phase 1 | C |
PREDNISONE TABLETS SciClone Pharmaceuticals | D |
Same molecule, other indications
Elacestrant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →